Lifeline for HAE patients: study offers continued access to promising treatment
NCT ID NCT04933721
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study gives people with hereditary angioedema (HAE) who were in earlier berotralstat trials continued access to the medication. About 139 participants will receive berotralstat and be monitored for side effects. The goal is to keep treating their condition while gathering more safety information.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study Center
Ottawa, Canada
-
Study Center
Brno, Czechia
-
Study Center
Pilsen, Czechia
-
Study Center
Grenoble, France
-
Study Center
Marseille, France
-
Study Center
Paris, France
-
Study Center
Frankfurt, Germany
-
Study Center
Skopje, North Macedonia
-
Study Center
Krakow, Poland
-
Study Center
Martin, Slovakia
-
Study Center
Cape Town, South Africa
-
Study Center
Daegu, South Korea
-
Study Center
Gwangju, South Korea
-
Study Center
Seoul, South Korea
-
Study Center
Madrid, Spain
-
Study Center
Bristol, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New oral option may offer relief for hereditary angioedema attacks
- Can a new injection tame hereditary swelling attacks?
- Could a simple pill shield HAE patients from Procedure-Triggered attacks?
- Teens with rare swelling disorder get new drug tested
- New drug shows promise for controlling rare swelling disorder
- New drug navenibart aims to tame hereditary swelling attacks